Compare JBS N.V. Class A Common Shares (JBS) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs DENTSPLY SIRONA Inc — how do they compare? JBS N.V. Class A Common Shares trades at $13 (market cap $13.86B), while DENTSPLY SIRONA Inc trades at $8.54 (market cap $1.70B). The key difference: JBS N.V. Class A Common Shares is far larger — about 8.2× DENTSPLY SIRONA Inc's market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.38%). Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| JBS | XRAY | |
|---|---|---|
Market Cap | $13.86B | $1.70B |
Volume | 4,980,049 | 3,939,845 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $14.68 |
52-Week Low | $10.86 | $8.44 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $34.83B | $3.77B |
Dividend Yield | 10.38% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
XRAY trades at $8.44, down 1.06% on the day and near its 52-week low, reflecting persistent bearish technical signals. The company reported a net loss of $598 million in 2025, with negative profit margins and declining revenue, though Q2 2026 earnings beat expectations. Debt-to-asset ratio has risen to 42.88% in 2025, indicating increased financial leverage amid ongoing restructuring efforts.
The outlook remains challenging with weak profitability and high debt, but analyst consensus suggests potential upside to a $13.00 price target. Key risks include margin pressure, competitive threats, and execution of the turnaround plan. Investment appeal hinges on successful operational improvements and sustained earnings recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
